View Older Stories
-
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
-
Envoy Medical completes enrollment for fully implanted cochlear trial
-
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
-
Envoy Medical shares six-month clinical data from cochlear implant study
-
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
-
Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
-
Envoy Medical adds Chas McKhann to board of directors
-
Envoy Medical Appoints Chas McKhann to Board of Directors
-
Envoy Medical first patients reach 12-month trial endpoint for implant
-
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
-
H.C. Wainwright Starts Envoy Medical (COCH) at Buy
-
Envoy Medical Reports Full Year 2025 Financial Results
-
Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
-
Envoy Medical regains Nasdaq compliance after meeting listing requirements
-
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
-
Envoy Medical receives three new patents for hearing implant technology
-
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
-
Envoy Medical raises $30 million, nears clinical trial completion
-
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
-
Envoy Medical Nears Completion of Enrollment in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
-
Envoy Medical closes $78 million public offering with milestone warrants
-
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering
-
Envoy Medical prices $78 million public offering with milestone warrants
-
Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering
-
Envoy Medical reaches midpoint enrollment in cochlear implant study
-
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
-
Envoy Medical receives Australian patent for cochlear implant technology
-
Envoy Medical Secures New Australian Patent for Cochlear Implant Innovation Aimed at Enhancing Input Signal-to-Noise Ratio
-
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
-
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
-
Envoy Medical Announces the Grant of Its 40th U.S. Patent
-
Envoy Medical (COCH) filed for 15.12M share offering by selling stockholders
-
Envoy Medical Secures New U.S. Patent for Innovative Cochlear Implant System Featuring a Removable Earplug Sensor and an Implanted Battery
-
Envoy Medical Achieves Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial
-
Envoy Medical Reports Third Quarter 2025 Financial and Operational Results
-
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
-
Envoy Medical Marks Three-Year Anniversary of First Patient Receiving Its Breakthrough Fully Implanted Cochlear Implant
-
Envoy Medical receives Nasdaq listing extension until February 2026
-
Envoy Medical Receives Positive Listing Determination from NASDAQ
-
Envoy Medical (COCH) files for 15.12M share offering by selling stockholders
-
Envoy Medical closes $16 million registered direct offering
-
Envoy Medical Announces Closing of Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Envoy Medical raises $4 million in registered direct offering
-
Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates
-
Envoy Medical Announces up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Envoy Medical gets FDA approval to advance cochlear implant trial
-
Envoy Medical Receives FDA Approval to Advance Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data
-
Envoy Medical to Participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) Conference on October 11th-14th
-
Envoy Medical closes $2.5M stock offering at $1.31 per share
-
Envoy Medical Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

